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G-CSF Is an Essential Regulator of Neutrophil
Trafficking from the Bone Marrow to the Blood
blood barrier) that separates the hematopoietic com-
partment from the circulation (Petrides and Dittmann,
1990). Bone marrow venous sinuses are the sites of
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neutrophil egress from the hematopoietic compartmentDepartment of Internal Medicine
and represent the only complete barrier to the intravas-Washington University School of Medicine
cular space. The sinus wall is a trilaminar structure com-St. Louis, Missouri 63110
posed of endothelial cells, a basement membrane, and
a layer of adventitial cells (Campbell, 1972; Inoue and
Osmond, 2001). A notable feature of neutrophil releaseSummary
from the bone marrow is the diversity of mobilizing
agents. Agents with distinct cellular targets and biologi-Neutrophils are released from the bone marrow in a
cal activities can induce neutrophil release from theregulated fashion to maintain homeostatic levels in
bone marrow including certain chemokines and cyto-the blood and to respond to physiological stresses,
kines, microbial products (e.g., N-formyl-methionyl-leu-including infection. We show that under basal condi-
cyl-phenylalanine [fMLP]), and various other inflamma-tions granulocyte colony-stimulating factor (G-CSF) is
tory mediators (e.g., C5a) (Jagels and Hugli, 1992, 1994;an essential regulator of neutrophil release from the
Opdenakker et al., 1998). Though many of the mobilizingbone marrow. Nonredundant signals generated by the
agents are capable of directly activating neutrophils, itmembrane-proximal 87 amino acids of the G-CSF recep-
is not a prerequisite for induction of neutrophil mobiliza-tor (G-CSFR) are sufficient to mediate this response.
tion. For example, hematopoietic growth factors thatSurprisingly, G-CSFR expression on neutrophils is nei-
predominantly target T lymphocytes (interleukin-7) andther necessary nor sufficient for their mobilization
dendritic cells (flt-3 ligand) lead to neutrophil mobiliza-from the bone marrow, suggesting that G-CSF induces
tion (Brasel et al., 1996; Grzegorzewski et al., 1994; Moli-neutrophil mobilization indirectly through the genera-
neux et al., 1997).tion of trans-acting signals. Evidence is provided sug-
Granulocyte colony-stimulating factor (G-CSF), thegesting that downregulation of stromal cell-derived
principal hematopoietic cytokine regulating granulo-factor 1 expression in the bone marrow may represent
poiesis, is widely used to treat or prevent neutropeniasuch a signal.
in a variety of clinical settings. In addition to its well-
characterized ability to induce neutrophil production,Introduction
G-CSF is a potent stimulus for inducing neutrophil re-
lease from the bone marrow. In mice, a single injectionNeutrophils, under normal conditions, are produced
of G-CSF induces a transient neutropenia followed bysolely in the bone marrow and are released into the
a 5-fold increase in circulating neutrophils that begins atblood in a regulated fashion to maintain homeostatic
30 min and peaks at 12 hr postinjection and is associatedlevels of circulating neutrophils. There are two major
with a modest but significant decrease in mature neutro-observations suggesting that neutrophil release from
phils in the bone marrow (Ulich et al., 1988). Maturethe bone marrow is a highly regulated process. First, in
and immature (band) neutrophils but not lymphocytesresponse to inflammatory stimuli, such as infection, the
or eosinophils are mobilized into the circulation, demon-number of neutrophils mobilized from the bone marrow
strating that G-CSF-induced mobilization is selective foris rapidly increased. Second, under normal conditions,
neutrophils. Similar data have been observed during
only mature neutrophils and not granulocytic precursors
G-CSF treatment in humans (Cohen et al., 1987). In re-
are released in significant numbers into the blood.
sponse to infection, the serum level of G-CSF is often
Though neutrophils play a critical role in innate immune increased, suggesting that G-CSF may play a key role
responses, there is increasing evidence that they also in regulating neutrophil release during stress conditions
may be a major contributor to tissue damage in inflam- (Kawakami et al., 1990).
matory diseases. Thus, regulation of circulating neutro- We previously reported the generation of transgenic
phil levels may be important in controlling both infectious mice carrying a targeted (knock-in) mutation of their
and inflammatory diseases. Moreover, perturbations in G-CSFR such that the cytoplasmic (signaling) domain
the control of leukocyte egress from the bone marrow of the G-CSFR is replaced with that of the erythropoietin
may contribute to the pathogenesis of leukemias. For receptor (EpoR) (Semerad et al., 1999). The resulting
example, in chronic myelogenous leukemia, expression chimeric receptor (termed GEpoR) is predicted to bind
of the bcr-abl oncogene may, via direct effects on cell G-CSF but transmit EpoR-specific signals. Mice homo-
adhesion and motility, contribute to the premature re- zygous for GEpoR are neutropenic, and treatment with
lease of immature myeloid cells (Salgia et al., 1997). G-CSF fails to induce significant mobilization of neutro-
The mechanisms that regulate neutrophil release from phils to the blood, despite near normal levels of mature
the bone marrow into the blood are largely undefined. neutrophils in the bone marrow. These data raised the
To enter the circulation, neutrophils must migrate possibility that nonredundant G-CSFR signals may be
through the vascular barrier (termed the bone marrow- important regulators of neutrophil trafficking from the
bone marrow. In the present study, this hypothesis is
confirmed and the nature of these signals is examined.1Correspondence: dlink@im.wustl.edu
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Figure 1. Neutrophil Response to G-CSF Treatment
(A) Long-term neutrophil response to G-CSF treatment. Mice (n  6) were treated with G-CSF (250 g/kg/day) for 7 days, and the number of
neutrophils (PMN) in the bone marrow (BM) and blood were quantified before (Day 0) and after treatment with G-CSF (Day 7). Neutrophil
distribution was estimated using the formula shown.
(B) Short-term neutrophil response to G-CSF treatment. Mice (n  3) were given a single subcutaneous injection of G-CSF (125 g/kg), and
the absolute neutrophil count was determined at the indicated times. Data represent the mean  SD. *, p  0.05 compared with similarly
treated WT mice.
We show that G-CSFR expression on neutrophils is nei- total body neutrophils are found in the blood. Following
G-CSF treatment, this percentage increases to 9.84 ther necessary nor sufficient for their mobilization by
G-CSF. The data suggest a model in which G-CSF acts, 2.22%, consistent with G-CSF’s ability to induce neutro-
phil release from the bone marrow. In contrast, onlyin trans, to induce neutrophil mobilization from the bone
marrow to the blood. 0.08  0.02% of neutrophils are in the blood of GEpoR
mice at baseline, and G-CSF treatment induced a mini-
mal redistribution of neutrophils from the bone marrowResults
to the blood (0.56  .24%) (Figure 1A).
To further characterize neutrophil release from theNeutrophil Mobilization into the Blood by G-CSF
Is Impaired in GEpoR Mice bone marrow, the short-term blood neutrophil response
to a single injection of G-CSF was determined. The acuteNeutrophil mobilization by G-CSF was characterized in
GEpoR mice inbred onto a C57BL/6 background. In response to G-CSF is thought to primarily reflect neutro-
phil mobilization from the bone marrow to the blood,GEpoR mice, treatment with G-CSF for 7 days resulted
in a 2-fold increase in bone marrow neutrophils resulting since G-CSF treatment has no effect on neutrophil sur-
vival in vivo and the time period examined is too brief toin a bone marrow neutrophil count similar to that seen
in wild-type mice (Figure 1A). Surprisingly, despite the reflect G-CSF-driven neutrophil production (Lord, 1992;
Lord et al., 1991). In response to a single subcutaneousincrease in bone marrow neutrophils to wild-type levels,
little increase in circulating neutrophils was observed in injection of G-CSF, wild-type mice exhibited a 2.5-fold
increase in circulating neutrophils 3 hr postinjection (Fig-GEpoR mice (Figure 1A). In fact, even in untreated
GEpoR mice, the severity of neutropenia is out of pro- ure 1B). In contrast, little neutrophil response to G-CSF
was evident in GEpoR mice.portion to the neutrophil content in the bone marrow.
Since the great majority of neutrophils reside in the bone
marrow and blood (Liu et al., 1997), we approximated Neutrophil Survival in the Blood Is Normal
in GEpoR Micethe tissue distribution of neutrophils by plotting the per-
centage of neutrophils in the blood versus the total num- There are at least three potential explanations for the
peripheral neutropenia observed in GEpoR mice. First,ber of neutrophils in the bone marrow and blood (Figure
1A). In wild-type mice, at baseline 0.79  0.31% of the neutrophil survival in the circulation of GEpoR mice may
Neutrophil Release from the Bone Marrow
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Figure 2. Fate of Brd-U-Labeled Neutrophils
Brd-U was administered to wild-type and
GEpoR mice by a single intraperitoneal injec-
tion at time zero. Immediately following Brd-U
administration, mice were treated with human
G-CSF (250 g/kg/day) for up to 7 days.
Blood and bone marrow cells were harvested
at the indicated times, and the number of Brd-
U/Gr-1 cells was determined by flow cy-
tometry. Each data point represents the mean
of two mice.
be significantly reduced. Second, neutrophil mobiliza- though reduced compared with wild-type mice. How-
ever, after accounting for the reduced number of neutro-tion from the bone marrow to the blood in response to
G-CSF may be defective in GEpoR mice. Third, neutro- phils in the bone marrow of GEpoR mice (70% that
of wild-type mice, Figure 1A), it is clear that maturephils mobilized from the bone marrow in GEpoR mice
may accumulate in the marginated pool or tissues. The neutrophils in GEpoR mice are capable of mobilizing in
response to IL-8.latter possibility seems unlikely, since no evidence of
neutrophil accumulation in the spleen or nonhematopoi-
etic tissues has been observed in GEpoR mice (data not The Membrane-Proximal Region of the G-CSFR Is
shown). Sufficient to Mediate G-CSF-Induced Neutrophil
To investigate potential differences in neutrophil sur- Mobilization from the Bone Marrow
vival, wild-type and GEpoR mice were given a single To define the region(s) of the G-CSFR required for neu-
intraperitoneal injection of 5-Bromo-2-deoxyuridine trophil mobilization, neutrophil distribution after 7 days
(Brd-U) immediately followed by G-CSF treatment for 7 of G-CSF treatment was examined in transgenic mice
days. The fate of blood and bone marrow neutrophils expressing a series of targeted mutations of their
pulse-labeled with Brd-U in vivo was determined by flow G-CSFR (Figure 4A). The d715 G-CSFR mutation intro-
cytometry. Surprisingly, the kinetics of the appearance duces a premature stop codon at nucleotide 2403, lead-
and subsequent disappearance of Brd-U neutrophils ing to truncation of the carboxy-terminal 96 amino acids
in the bone marrow and blood were similar between of the G-CSFR (McLemore et al., 1998). It is representa-
wild-type and GEpoR mice (Figure 2). The half-life (t1/2) tive of G-CSFR mutations found in approximately 25% of
of peripheral neutrophils is calculated from the rate of patients with severe congenital neutropenia. However,
loss of labeled cells in the blood using the formula N  mice homozygous for the d715 G-CSFR mutation have
Noe-t, in which No  peak number of cells, N  number normal basal hematopoiesis. In the d715F G-CSFR mu-
of cells at time t, and   the decay constant (Lord et tant, the sole remaining tyrosine (Y704) of d715 has
al., 1991). The calculated half-lives for wild-type and
GEpoR neutrophils were similar (8.6 and 9.8 hr, respec-
tively) and are consistent with previously published data
for wild-type neutrophils in mice and humans (Lord et al.,
1989, 1991). A similar neutrophil half-life was observed in
mice without G-CSF treatment (data not shown). Collec-
tively, these data suggest that GEpoR signals, while able
to support near normal neutrophil production, are not
able to induce neutrophil mobilization from the bone
marrow.
IL-8-Mediated Neutrophil Release from the Bone
Marrow Is Normal in GEpoR Mice
To determine whether the defect in neutrophil mobiliza-
tion is specific to G-CSF or representative of a more
global defect, we characterized neutrophil mobilization
by interleukin-8 (IL-8) in GEpoR mice. As reported pre-
viously, treatment of wild-type mice with a single intra-
Figure 3. Neutrophil Response to IL-8 Administration
peritoneal injection of IL-8 induced a rapid increase in
Human recombinant IL-8 (2 g/mouse) was given to wild-type andthe level of circulating neutrophils that peaked within
GEpoR mice (n  5) by a single intraperitoneal injection. Peripheral
30 min and subsided by 6 hr postinjection (Figure 3) blood was obtained at the indicated times, and the absolute neutro-
(Laterveer et al., 1995; Liu et al., 1997). In GEpoR mice, phil count was determined. Data represent the mean  SD. *, p 
0.05 compared with WT mice.IL-8 induced a significant increase in blood neutrophils,
Immunity
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Figure 4. Neutrophil Mobilization by G-CSF in G-CSFR Mutant Mice
(A) Schematic of targeted G-CSFR mutations. Cytoplasmic tyrosines (Y) and the conserved box 1 and box 2 motifs are indicated. In the d715F
mutant, tyrosine 704 of the G-CSFR has been mutated to phenylalanine (F).
(B) Neutrophil distribution. Mice (n  3, each) were treated with G-CSF (250 g/kg/day) for 7 days, and the neutrophil content of bone marrow
and blood was measured on days 0 and 7. Neutrophil distribution was calculated as shown in Figure 1. Data represent the mean  SD. *,
p  0.05 compared with similarly treated WT mice.
been mutated to phenylalanine (McLemore et al., 2001). G-CSF-induced neutrophil mobilization into the blood
was normal.Importantly, STAT 3 and STAT 5 activation by the d715F
G-CSFR is markedly impaired. Mice homozygous for the The failure of GEpoR neutrophils to mobilize from the
bone marrow in response to G-CSF may be due to thed715F G-CSFR display an isolated defect in granulo-
poiesis. All mice were inbred on a C57BL/6 background. loss of nonredundant G-CSFR signals that promote neu-
trophil mobilization from the bone marrow. Alternatively,In G-CSFR-deficient (/) mice, the percentage of neu-
trophils in the blood at baseline was reduced compared it is possible the GEpoR transmits an aberrant signal
that interferes with neutrophil mobilization. To addresswith wild-type mice (WT versus G-CSFR/, 0.79 
0.31% versus 0.25  0.05%), and little change was ob- this issue, we generated an additional series of bone
marrow chimeras using wild-type and G-CSFR-deficientserved after G-CSF treatment, as expected (Figure 4B).
In both d715 and d715F mice, at baseline the percentage mice (data not shown). Similar to the GEpoR chimeras,
in irradiated wild-type mice reconstituted with G-CSFR-of neutrophils in the blood was modestly reduced com-
pared to wild-type mice (d715, 0.45  0.04%; d715F, deficient hematopoiesis, no G-CSF-induced neutrophil
mobilization was observed. Conversely, in irradiated0.15  0.03%). In contrast, after G-CSF treatment the
redistribution of neutrophils into the blood was compa- G-CSFR-deficient mice reconstituted with wild-type he-
matopoiesis, G-CSF-induced neutrophil mobilizationrable in wild-type (9.84 2.22%) and d715F mice (13.0
8.90%) and was greater in d715 mice (39.6  2.92%). into the blood was normal. Collectively, these data dem-
onstrate that expression of the G-CSFR on transplant-These data show that the membrane-proximal 87 amino
acids of the G-CSFR are sufficient to mediate G-CSF- able hematopoietic cells—not stromal cells—is required
for G-CSF-induced neutrophil mobilization from thedependent neutrophil mobilization from the bone mar-
row and suggest the presence of an inhibitory domain bone marrow to the blood.
in the carboxy-terminal tail of the G-CSFR.
Expression of the G-CSFR on Neutrophils Is Neither
Necessary nor Sufficient for Their MobilizationExpression of the G-CSFR on Transplantable
Hematopoietic Cells but Not Stromal Cells Is from the Bone Marrow by G-CSF
Within the transplantable hematopoietic cell compart-Required for Neutrophil Mobilization by G-CSF
The G-CSFR is expressed on subsets of hematopoietic ment, the G-CSFR is expressed on neutrophils, hemato-
poietic progenitor cells (HPC), monocytes, platelets, andcells and stromal cells. Within the stromal cell compart-
ment, the G-CSFR is expressed on endothelial cells and possibly natural killer (NK) and B cells (Demetri and
Griffin, 1991; Iizuka et al., 1997; Inukai et al., 1995; Nicolais capable of inducing endothelial cell proliferation (Boc-
chietto et al., 1993). To characterize the cell type(s) re- and Metcalf, 1985). G-CSFR signals generated in any
or all of these cell types may contribute to neutrophilsponsible for G-CSF-dependent neutrophil mobilization,
a series of bone marrow chimeras was generated using mobilization from the bone marrow. To determine
whether a functional G-CSFR on neutrophils is requiredwild-type and GEpoR mice (Figure 5A). In irradiated wild-
type mice reconstituted with GEpoR hematopoiesis for G-CSF-induced neutrophil mobilization, a series of
mixed bone marrow chimeras was generated in which(GE 	 WT), no G-CSF-induced neutrophil mobilization
was observed. Conversely, in irradiated GEpoR mice mice were reconstituted with both G-CSFR-deficient
and wild-type hematopoiesis. If expression of the G-CSFRreconstituted with wild-type hematopoiesis (WT 	 GE),
Neutrophil Release from the Bone Marrow
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Figure 5. G-CSF-Induced Neutrophil Mobilization in Chimeric Mice
(A) G-CSF-induced neutrophil mobilization in bone marrow chimeras. Irradiated GEpoR mice reconstituted with wild-type hematopoiesis (WT	
GE) and irradiated wild-type mice reconstituted with GEpoR hematopoiesis (GE 	 WT) were treated with PBS alone or G-CSF for 7 days, and
the number of neutrophils in the blood and bone marrow was quantified. Data represent the mean  SD of six mice. *, p  0.05 compared
with similarly treated WT 	 GE chimeras.
(B) Representative flow cytometry histograms of bone marrow and blood from a 3:1 G-CSFR-deficient:WT chimera stained with antibodies
against Gr-1 and Ly 5.2. Note the great majority of the Gr-1 bright cells (mature neutrophils) in the bone marrow and blood are Ly 5.2 negative
(i.e., of wild-type origin). Sorting of Gr-1 bright cells from the bone marrow, based on the gates shown, established that greater than 90% of
the cells were mature neutrophils (data not shown).
(C) G-CSF-induced neutrophil mobilization in the mixed chimeras. Mixed chimeras transplanted with the indicated ratio of G-CSFR-deficient
to wild-type bone marrow cells or mice transplanted solely with wild-type cells (W 	 W) were treated with G-CSF and neutrophil mobilization
characterized. The number of wild-type and G-CSFR-deficient neutrophils in the blood and bone marrow of these chimeras is shown separately.
Data represent the mean  SD of six mice. *, p  0.05 compared with W 	 W chimeras.
on neutrophils is required for their mobilization from the Mixed chimeras were generated by mixing G-CSFR-
deficient and wild-type bone marrow cells at ratios ofbone marrow, then treatment of these mixed chimeras
with G-CSF would be predicted to mobilize only wild- 1:1, 3:1, and 9:1 (G-CSFR-deficient:wild-type) and trans-
planting them into irradiated syngeneic wild-type mice.type neutrophils.
Immunity
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Table 1. Donor Origin in Mixed Chimeras
Blood
Chimera Bone Marrow
KO:WT B Lymphocytes T Lymphocytes Neutrophils Neutrophils
1:1 53.5  9.3% 55.9  10.7% 96.5  2.0% 96.3  1.4%
3:1 32.2  6.8% 38.9  8.1% 96.0  2.3% 92.9  2.0%
9:1 18.7  6.6% 21.2  5.5% 92.0  5.1% 90.2  4.1%
Percentage of wild-type cells within a given lineage is shown for each group of chimeras 3 months posttransplant (n  6, each). Data represent
the mean  SD.
In these experiments, congenic wild-type mice carrying expression on neutrophils is neither necessary nor suffi-
cient for G-CSF-induced neutrophil mobilization fromthe Ly 5.1 allele were used to facilitate chimerism analy-
sis (G-CSFR-deficient mice are Ly 5.2). To control for the bone marrow to the blood.
the bone marrow transplant procedure, a cohort of wild-
type mice reconstituted solely with wild-type bone mar- G-CSF-Induced Decrease in Bone Marrow SDF-1
Correlates with Neutrophil Mobilizationrow cells also were studied. Mice were analyzed 3
months posttransplantation by flow cytometry to assess Accumulating evidence suggest that the chemokine
stromal-derived factor-1 (SDF-1) may be a key retentionthe contribution of wild-type (Ly 5.1) versus G-CSFR-
deficient (Ly 5.2) cells to each hematopoietic lineage signal in the bone marrow for hematopoietic cells (Kawa-
bata et al., 1999; Ma et al., 1999; Nagasawa et al., 1996).(Figure 5B and Table 1). Peripheral blood counts, includ-
ing neutrophils, were similar in all groups of chimeric To determine whether modulation of SDF-1 expression
in the bone marrow may regulate neutrophil trafficking,mice (data not shown). The contribution of G-CSFR-
deficient cells to the B- and T-lymphocyte lineages was we measured SDF-1
 protein levels in the bone marrow
and blood of wild-type mice and mice displaying im-near the predicted levels. However, the contribution of
G-CSFR-deficient cells to the granulocytic lineage was paired neutrophil mobilization (i.e., GEpoR mice and the
3:1 and 9:1 mixed chimeras). G-CSF treatment inducedprofoundly impaired, such that in the 3:1 mixed chime-
ras, 96.0% of blood neutrophils and 92.9% of bone mar- a significant decrease in SDF-1
 protein levels in the
bone marrow and blood of wild-type mice (Figure 6A).row neutrophils were of wild-type origin. A detailed de-
scription of the effect of the loss of the G-CSFR on In contrast, no change in SDF-1
 expression was de-
tected in GEpoR mice following G-CSF treatment. More-granulopoiesis will be presented elsewhere (Richards et
al., submitted). over, G-CSF treatment induced a much more modest
decrease in SDF-1
 in the bone marrow and blood ofThe mixed chimeras were treated with G-CSF for 7
days, and the neutrophil response in the bone marrow the mixed chimeras (Figure 6B and data not shown). In
fact, a strong correlation was observed between theand blood was examined (Figure 5C). These studies
yielded two important observations. First, though the degree of neutrophil mobilization by G-CSF and the
magnitude of the decrease in bone marrow SDF-1
 (Fig-total number of neutrophils mobilized into the blood was
reduced in the mixed chimeras relative to their number ure 6C, r2  .919).
in the bone marrow (see below), G-CSFR-deficient neu-
trophils were mobilized at least as well as wild-type Discussion
neutrophils. For example, in the 3:1 chimeras, 2.91 
1.01% of wild-type and 6.54  1.32% of G-CSFR-defi- Neutrophils are released from the bone marrow in a
regulated fashion to maintain homeostatic levels and tocient neutrophils were distributed into the blood after
G-CSF treatment. These data indicate that a functional increase their number in response to stresses, including
infection. Despite their clinical and biological impor-G-CSFR on neutrophils is not required for their mobiliza-
tion from the bone marrow to the blood by G-CSF. Sec- tance, the mechanisms that regulate neutrophil egress
from the bone marrow are poorly understood. In thisond, the presence of G-CSFR-deficient hematopoietic
cells inhibited mobilization of wild-type neutrophils in study, we show that G-CSFR signals are required to
maintain basal levels of circulating neutrophils, in largea dose-dependent fashion in the mixed chimeras. For
example, comparing the 3:1 chimera to mice reconstitu- part, through regulation of their release from the bone
marrow. In fact, the major mechanism by which G-CSFted with only wild-type cells, the absolute neutrophil
count in the blood was 2.93  .84  106 versus 14.2  treatment results in an increased number of neutrophils
in the blood is through their augmented release. For5.7  106 neutrophils/ml, respectively. Importantly, the
number of mature wild-type neutrophils in the bone mar- example, in wild-type mice at baseline approximately
1% of total body neutrophils are in the blood, whereasrow of these mice was similar (9.67  1.2  106 versus
9.2  2  106 neutrophils/femur, respectively). Accord- after 7 days of G-CSF treatment, this value increases
to approximately 10%. Interestingly, GEpoR, while ableingly, the redistribution of wild-type neutrophils from the
bone marrow to the blood was significantly reduced to transduce near normal proliferative signals in vivo,
is not able to transduce the signals generated by the(3:1 chimera versus WT chimera, 2.91  1.01% versus
14.32  4.82%, p  .05). Similar results were observed G-CSFR that mediate neutrophil release, raising the pos-
sibility that unique G-CSFR signals may mediate thisin mixed chimeras generated by transplanting a combi-
nation of GEpoR and wild-type bone marrow cells (data biological response. Of note, all of the mice in this study
were maintained in a specific pathogen-free (SPF) envi-not shown). Collectively, these data show that G-CSFR
Neutrophil Release from the Bone Marrow
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Figure 6. G-CSF-Induced Changes in
SDF-1
 Protein Expression
(A and B) Wild-type and GEpoR mice (A) (n 
6) and G-CSFR-deficient:wild-type mixed chi-
meras (B) (n  3) were treated with G-CSF
(250 g/kg/day) for 5 days, and the amount
of SDF-1
 protein in the bone marrow extra-
cellular fluid and plasma was measured by
ELISA. Data represent the mean  SD. *, p 
0.05 compared with untreated control mice.
(C) The magnitude of the decrease in SDF-
1
 protein in the bone marrow was estimated
by dividing the average amount of SDF-1

protein present in G-CSF-treated mice by un-
treated mice. This value was plotted against
neutrophil mobilization, as measured by the
percentage of total body neutrophils present
in the blood after G-CSF treatment.
ronment. The contribution of G-CSFR signals to the reg- layed receptor internalization, sustained STAT activa-
tion, and/or the failure to recruit the SH2 domain-ulation of neutrophil trafficking under a more natural
environment in which mice are continuously exposed containing phosphatase-1 (SHP-1) (Dong et al., 2001;
Hermans et al., 1999; Hunter and Avalos, 1999). G-CSFto pathogens is not clear.
The importance of G-CSF in the regulation of neutro- also induced significant neutrophil mobilization in d715F
G-CSFR mice. These data indicate that STAT 3 andphil release during stress conditions has been assessed
in G-CSF-deficient mice in response to infection with STAT 5 activation by the G-CSFR is not required for the
transduction of signals leading to neutrophil release,Listeria monocytogenes or Candida albicans (Basu et
al., 2000; Lieschke et al., 1994). The acute neutrophilia since their activation by the d715F G-CSFR is markedly
impaired (McLemore et al., 2001). The membrane-proxi-associated with Listeria monocytogenes infection was
blunted in G-CSF-deficient mice. Surprisingly however, mal 87 amino acids of the G-CSFR is sufficient to induce
the activation of JAK and src family tyrosine kinases,a similar increase in the level of circulating neutrophils
was observed in wild-type and G-CSF-deficient mice the PI3kinase/Akt pathway, and some components of
the Ras/MAPK pathway (Avalos et al., 1995; Dong andafter challenge with Candida albicans. These studies
show that G-CSF may play an important role in regulat- Larner, 2000; Rausch and Marshall, 1997). Studies are
under way to assess the contribution of these signaling neutrophil release in response to some but not all
infections. Consistent with this conclusion, we show in transduction pathways in G-CSF-induced neutrophil
mobilization.the present study that IL-8-induced neutrophil mobiliza-
tion in GEpoR mice is comparable to wild-type mice. The G-CSFR is expressed on a broad range of hema-
topoietic and bone marrow stromal cells, including en-Clearly, G-CSFR signals are not universally required for
neutrophil release from the bone marrow. dothelial cells, neutrophils, monocytes, progenitors, and
possibly natural killer and B cells (Demetri and Griffin,To begin to define the region(s) of the G-CSFR that
mediate neutrophil release from the bone marrow, we 1991; Iizuka et al., 1997; Inukai et al., 1995; Nicola and
Metcalf, 1985). To identify the cell type(s) that mediatecharacterized neutrophil mobilization by G-CSF in a se-
ries of transgenic mice carrying different targeted G-CSF-induced neutrophil mobilization, a series of bone
marrow chimeras between wild-type and G-CSFR mu-G-CSFR mutations. These data show that the mem-
brane-proximal 87 amino acids of the G-CSFR are suffi- tant mice were generated. Previous studies showed
that, following bone marrow transplantation, the greatcient to induce neutrophil release from the bone marrow.
In fact, neutrophil mobilization in d715 G-CSFR mice majority of bone marrow stromal cells are of recipient
origin (Lennon and Micklem, 1986; Simmons et al., 1987).is significantly increased compared to wild-type mice,
suggesting the presence of an inhibitory domain in the Thus, our studies of the WT	GE and GE	WT chimeras
(Figure 5A) strongly suggest that G-CSFR expressioncarboxy-terminal tail of the G-CSFR. Interestingly, previ-
ous studies showed that the d715 G-CSFR also displays on stromal cells is not required for neutrophil mobiliza-
tion by G-CSF. Studies of neutrophil mobilization inenhanced proliferative signaling, possibly through de-
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progenitors from the fetal liver to the bone marrow (Ma
et al., 1999; Nagasawa et al., 1996). Moreover, in mice
reconstituted with CXCR4-deficient bone marrow cells,
premature release of granulocytic precursors was ob-
served (Kawabata et al., 1999; Ma et al., 1999). Finally,
elevation of SDF-1 levels in the blood by administration
of SDF-1 or by injection of an adenoviral vector express-
ing SDF-1 is associated with a significant mobilization
of hematopoietic progenitors and mature leukocytes
into the blood (Hattori et al., 2001; Moore et al., 2001).
These data suggest that SDF-1 may be a key retention
signal in the bone marrow for both hematopoietic pro-
genitors and mature leukocytes, including neutrophils.
In the present study, we show that G-CSF treatment
results in a significant decrease in SDF-1
 protein in the
bone marrow and blood of wild-type mice. Importantly,
the decrease in SDF-1
 in the bone marrow was attenu-
ated or absent in mice displaying impaired neutrophil
mobilization by G-CSF (i.e., GEpoR mice and the mixed
chimeras). In fact, a strong correlation was observed
between the degree of neutrophil mobilization by G-CSF
and the magnitude of the decrease in bone marrow
Figure 7. Two-Step Model of G-CSF-Induced Neutrophil Mobili- SDF-1
 (Figure 6C). Consistent with our data, Petit and
zation
colleagues also reported that SDF-1 protein levels de-
In this model, G-CSF engages its receptor on a (as yet undefined)
creased in the bone marrow after G-CSF treatment (Petittarget cell population, resulting in its activation. Following activation,
et al., 2002). Moreover, they showed that treatment ofthis cell population generates secondary signals that act in trans to
mice with neutralizing SDF-1 or CXCR4 antibodies par-induce neutrophil mobilization from the bone marrow.
tially inhibited hematopoietic cell mobilization by G-CSF
(though neutrophils were not specifically measured). In-
terestingly, they also provided evidence that the de-mixed chimeras reconstituted with both wild-type and
crease in SDF-1 protein in the bone marrow is secondaryG-CSFR mutant hematopoiesis yielded several signifi-
to its proteolytic degradation by neutrophil elastase.cant observations. First, relative to their number in the
However, we recently observed that G-CSF-inducedbone marrow, wild-type and G-CSFR mutant neutrophils
neutrophil mobilization is normal in neutrophil elastasewere mobilized equally by G-CSF (Figure 5C). This ob-
and cathepsin G-deficient mice, suggesting that multi-servation demonstrates that G-CSFR expression on
ple mechanisms may regulate SDF-1 expression (Le-neutrophils is not required for their mobilization by
vesque et al., submitted).G-CSF and suggests a trans-acting mechanism. Sec-
In summary, these data provide evidence that nonre-ond, despite a similar number of wild-type neutrophils
dundant G-CSFR signals play an important role in regu-in the bone marrow after G-CSF treatment in all of the
lating neutrophil release from the bone marrow andchimeras, the number of neutrophils mobilized into the
maintaining homeostatic levels of neutrophils in theblood decreased as the contribution of G-CSFR-defi-
blood. Surprisingly, G-CSFR expression on neutrophilscient cells increased (Table 1 and Figure 5C). This sur-
is neither necessary nor sufficient for their mobilizationprising observation demonstrates that expression of the
from the bone marrow by G-CSF, suggesting that G-CSFG-CSFR on neutrophils is not sufficient to induce their
induces neutrophil mobilization indirectly through themobilization by G-CSF. Collectively, our data support a
generation of trans-acting signals. Evidence is providedtwo-step model of G-CSF-induced neutrophil mobiliza-
suggesting that downregulation of stromal cell-derivedtion (Figure 7). In the first step, a (as yet undetermined)
factor 1 expression in the bone marrow may representsubset of hematopoietic cells is activated by nonredun-
such a signal. A better understanding of the mechanismsdant G-CSFR signals. The second step is the generation
that regulate neutrophil trafficking may lead to novelof secondary signals by these activated cells that act in
pharmacological strategies to modulate neutrophil re-trans to induce neutrophil release from the bone marrow.
sponses in host defense and inflammation.The nature of the secondary signal(s) that mediate
neutrophil mobilization by G-CSF is not known; how-
Experimental Proceduresever, there is accumulating evidence suggesting that
SDF-1 may play a key role in regulating hematopoietic Mice
cell trafficking from the bone marrow. SDF-1 is constitu- G-CSFR-deficient, GEpoR, d715, and d715F mice were generated
in our laboratory, as described previously (Liu et al., 1996; McLemoretively produced by bone marrow stromal cells (Aiuti et
et al., 1998, 2001; Semerad et al., 1999). Wild-type, G-CSFR-defi-al., 1997). CXCR4, the receptor for SDF-1, is expressed
cient, GEpoR, d715 G-CSFR, and d715F G-CSFR mice were back-on a broad range of hematopoietic cells including hema-
crossed ten generations onto a C57BL/6 background. Unless other-topoietic progenitors and neutrophils (Aiuti et al., 1997;
wise stated in the text, we used 6- to 10-week-old mice in all studies.
Bruhl et al., 2001; Nagase et al., 2002). Studies of mice Mice were housed in a specific pathogen-free environment. All ex-
lacking SDF-1 or CXCR4 have established that SDF-1 periments were approved by the Washington University Animal
Studies Committee.is necessary for the normal migration of hematopoietic
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Peripheral Blood and Bone Marrow Analysis used in this study stained positive only for Ly 5.1 while G-CSFR-
deficient and GEpoR cells stained positive only for Ly 5.2 (data notBlood was obtained by retroorbital venous plexus sampling in poly-
propylene tubes containing EDTA. Complete blood counts were shown). All samples were analyzed using a FACScan flow cytometer
and CellQuest version 1.2.2 software (Becton-Dickinson, Mans-determined using a Hemavet automated cell counter (CDC Technol-
ogies, Oxford, CT). Bone marrow was harvested by flushing with field, MA).
Hanks Balanced Salts containing 0.1% low endotoxin bovine serum
albumin (Sigma, St. Louis, MO). Manual leukocyte differentials were SDF-1 ELISA
performed on Wright-stained blood smears (300 cell count) or cyto- 96-well plates were coated with 100 l of SDF-1 capture antibody
spin preparations of bone marrow mononuclear cells (500 cell at 2g/ml, diluted in PBS, and incubated overnight at room tempera-
count). Neutrophil distribution was estimated by dividing the number ture. After incubation overnight at 4C with 300 l of blocking solu-
of neutrophils in the blood by the number of neutrophils in the tion (1% bovine serum albumin [BSA], 5% sucrose, and .05% NaN3),
blood and bone marrow. Blood and bone marrow neutrophils were 100l of sample diluted 1:3 (bone marrow) and 1:4 (plasma) in ELISA
calculated assuming a blood volume of 1.8 ml and a whole femur diluent (0.1% BSA, .05% Tween 20 in Tris-buffered saline at pH
equivalent to 6% of the total bone marrow (Chervenick et al., 1968). 7.3) was loaded and incubated for 2 hr at room temperature. After
Bone marrow extracellular fluid was obtained by flushing each femur washing, 100 l of polyclonal biotinylated anti-human SDF-1 at 250
with 1 ml of ice-cold PBS without serum, and the supernatant was ng/ml diluted in ELISA diluent was added to each well and incubated
harvested after centrifugation at 400 g for 5 min. at room temperature for 2 hr. The reaction was developed by succes-
sive incubations with 1 g/ml horseradish peroxidase streptavidin,
substrate solution, and 50 l of 2N H2SO4 to stop the reaction. AMobilization Protocols
microplate reader set at 450 nm was used to determine opticalRecombinant human G-CSF (Amgen, Thousand Oaks, CA) diluted
density with readings at 550 nm subtracted from the results. Recom-in PBS with 0.1% low endotoxin bovine serum albumin (Sigma, St.
binant human SDF-1
 was used to generate a standard curve. AllLouis, MO) was administered by daily subcutaneous injection at a
ELISA reagents were purchased from R&D Systems (Minneapo-dose of 250 g/kg per day for 7 days. Peripheral blood was obtained
lis, MN).before the first and 4 hr after the final injection of G-CSF. In some
experiments, mice were treated with a single subcutaneous injection
of G-CSF (125 g/kg), and peripheral blood was analyzed at the Statistical Analysis
indicated times. Recombinant human IL-8, a generous gift from Statistical significance was assessed using a two-sided Student’s
Searle Co. (now part of Pfizer Inc, New York, NY), was given by a t test.
single intraperitoneal injection, and peripheral blood was analyzed
at the indicated times. Acknowledgments
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